News
-
19.12.2022Captor Therapeutics senior management to hold investor and partnering meetings around J.P. Morgan 41st Annual Healthcare Conference
-
24.11.2022Captor Therapeutics reports Q3 2022 results and provides business update. Lead assets approaching the clinic and new significant drug discovery collaboration signed with Ono Pharmaceutical
-
14.11.2022Ono Pharmaceutical and Captor Therapeutics announce drug discovery collaboration to develop small molecule protein degraders for the treatment of neurodegenerative diseases
-
20.09.2022Captor Therapeutics announces participation in upcoming scientific, investor, and partnering conferences in October 2022
-
05.09.2022Captor Therapeutics' first half of 2022 marked by significant progress in R&D and preparations for the commencement of clinical trials
-
10.08.2022Captor Therapeutics nominates the molecular glue CPT-6281 as drug candidate to enter CTA/IND-enabling studies for the treatment of hepatocellular carcinoma
-
21.07.2022Captor Therapeutics to attend Wedbush PacGrow Healthcare Conference 2022
-
30.06.2022Zaproszenie na Walne Zgromadzenie
-
31.05.2022Captor Therapeutics Q1 2022 report: company continues to generate exciting data on lead projects (CT-01, CT-02, CT-03), maintains strong financial position
-
05.05.2022Captor Therapeutics to host R&D Day on May 18, 2022